The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.
Patients diagnosed with non-small-cell lung cancer (NSCLC) at a younger age are far more likely to harbor a targetable genomic alteration than older patients.
Comprehensive genomic profiling of patients with advanced urothelial carcinoma has revealed a very high frequency of clinically relevant genomic alterations.
A phase II trial found that use of a personalized peptide vaccination improved overall survival in patients with chemotherapy-resistant advanced urothelial bladder cancer.
Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.
The FDA granted accelerated approval to osimertinib (Tagrisso), previously known as AZD9291, for treatment of advanced non-small-cell lung cancer (NSCLC) with the EGFR mutation T790M.
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.
According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.